Heart failure & cardiomyopathiesResearch article
Contemporary American and European Guidelines for Heart Failure Management
- Narrative review
Study context
- Population
- Patients with heart failure (HF)
- Comparison
- 2021 European Society of Cardiology (ESC) guideline and 2023 focused update vs 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline
Main finding
As reported in the abstract
Comparison of ESC 2021/2023 and ACC/AHA/HFSA 2022 HF guideline recommendations
- All guidelines provide new recommendations: primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, cardiac and noncardiac comorbidities, device-based therapies, special groups incl. cardiac amyloidosis
- ACC/AHA/HFSA document: special emphasis on HF risk prediction and screening, cost/value, social determinants of health, health care disparities
Original publication
Contemporary American and European Guidelines for Heart Failure Management. JACC Heart Fail. Published 13 March 2024. doi:10.1016/j.jchf.2024.02.020
Summarised from the published abstract; every number is checked against it